Baseline | aMCI a (n = 240) | naMCI a (n = 240) | Control (n = 480) |
---|---|---|---|
Male (n, %) | 170 (70.8) | 176 (73.3) | 360 (75.0) |
Age (yrs, mean ± SD) a | 73.4 ± 7.7 | 72.6 ± 9.6 | 73.2 ± 6.8 |
Han nationality (n, %) | 224 (93.3) | 220 (91.7) | 460 (95.8) |
Education | |||
  ≤ 12 years | 112 (46.7) | 107 (44.6) | 231 (48.1) |
 >12 years | 128 (53.3) | 133 (55.4) | 249 (51.9) |
Type 2 DM (n, %) a | 70 (29.2) * | 66 (27.5) * | 84 (17.5) |
Hypertension (n, %) | 170 (70.8) * # | 198 (82.5) * | 256 (53.3) |
CHD (n, %) a | 98 (40.8) * # | 134 (55.8) * | 146 (30.4) |
MS (n, %) a | 62 (25.8) * | 60 (25.0) * | 76 (15.8) |
Sulfonylureas (n, %) | 33 (13.8) * | 35 (14.6) * | 41 (8.5) |
Metformin (n, %) | 45 (18.8) * | 43 (17.9) * | 61 (12.7) |
Insulin (n, %) | 13 (5.4) | 10 (4.2) | 15 (3.1) |
Statins (n, %) | 53 (22.1) * | 58 (24.2) * | 70 (14.6) |
APOE4 carriers (n, %) a | 72 (30.0) * | 61 (25.4) * | 90 (18.8) |